Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.

IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints

by Zacks Equity Research

IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.

Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates

by Zacks Equity Research

Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.

SmileDirectClub (SDC) Q3 Earnings Lag Estimates, Margin Grows

by Zacks Equity Research

SmileDirectClub (SDC) registered a year-over-year decline in revenues in the third quarter due to lower unique aligner shipment.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up

by Zacks Equity Research

Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.

AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

by Zacks Equity Research

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.

Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.

LHC Group (LHCG) Q3 Earnings Match Estimates, Down Y/Y

by Zacks Equity Research

LHC Group's (LHCG) third-quarter results benefit from organic growth in both home health and hospice admissions.

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

by Zacks Equity Research

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.

BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued

by Zacks Equity Research

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed

by Zacks Equity Research

Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.

STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.

    QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up

    by Zacks Equity Research

    QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.

    Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up

    by Zacks Equity Research

    Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

    Tandem Diabetes (TNDM) Q3 Earnings Top Estimates, Sales View Up

    by Zacks Equity Research

    Tandem Diabetes (TNDM) reports better-than-expected revenues for third-quarter 2021 as strong domestic and international pump shipments drive the top line.

      AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

      by Zacks Equity Research

      AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.